MET and non-small cell lung carcinoma: The mechanism of drug resistance of first/second-generation EGFR-TKIs in non-small cell lung cancer (NSCLC) is a secondary gene mutation, such as TK domain mutation (T790M), MET amplification, and RAS mutation6–8.